BRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BioRestorative Therapies's Total Assets for the quarter that ended in Sep. 2024 was $14.57 Mil.
During the past 12 months, BioRestorative Therapies's average Total Assets Growth Rate was -4.90% per year. During the past 3 years, the average Total Assets Growth Rate was 6.40% per year. During the past 5 years, the average Total Assets Growth Rate was 7.00% per year. During the past 10 years, the average Total Assets Growth Rate was 0.50% per year.
During the past 13 years, BioRestorative Therapies's highest 3-Year average Total Assets Growth Rate was 120.60%. The lowest was -16.60%. And the median was 6.40%.
Total Assets is connected with ROA %. BioRestorative Therapies's annualized ROA % for the quarter that ended in Sep. 2024 was -28.44%. Total Assets is also linked to Revenue through Asset Turnover. BioRestorative Therapies's Asset Turnover for the quarter that ended in Sep. 2024 was 0.02.
The historical data trend for BioRestorative Therapies's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
1.47 | 4.35 | 22.45 | 16.44 | 12.61 |
BioRestorative Therapies Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
13.80 | 12.61 | 17.95 | 16.12 | 14.57 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
BioRestorative Therapies's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (A: Dec. 2023 ) | + | Total Liabilities (A: Dec. 2023 ) |
= | 10.004 | + | 2.607 | |
= | 12.61 |
BioRestorative Therapies's Total Assets for the quarter that ended in Sep. 2024 is calculated as
Total Assets | = | Total Equity (Q: Sep. 2024 ) | + | Total Liabilities (Q: Sep. 2024 ) |
= | 9.992 | + | 4.582 | |
= | 14.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (NAS:BRTX) Total Assets Explanation
Total Assets is connected with ROA %.
BioRestorative Therapies's annualized ROA % for the quarter that ended in Sep. 2024 is
ROA % | = | Net Income (Q: Sep. 2024 ) | / | ( (Total Assets (Q: Jun. 2024 ) | + | Total Assets (Q: Sep. 2024 )) | / count ) |
= | -4.364 | / | ( (16.119 | + | 14.573) | / 2 ) | |
= | -4.364 | / | 15.346 | ||||
= | -28.44 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
BioRestorative Therapies's Asset Turnover for the quarter that ended in Sep. 2024 is
Asset Turnover | ||||||
= | Revenue (Q: Sep. 2024 ) | / | ( (Total Assets (Q: Jun. 2024 ) | + | Total Assets (Q: Sep. 2024 )) | / count ) |
= | 0.234 | / | ( (16.119 | + | 14.573) | / 2 ) |
= | 0.234 | / | 15.346 | |||
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of BioRestorative Therapies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Dale Broadrick | 10 percent owner | 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207 |
Francisco Silva | director, 10 percent owner, officer: VP of Research and Development | STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458 |
Lance Alstodt | director, 10 percent owner, officer: President, CEO, COB | BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747 |
Robert Eugene Kristal | officer: Chief Financial Officer | 4719 COLE AVENUE, DALLAS TX 75205 |
Patrick F. Williams | director | C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
David A Rosa | director | 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343 |
Nickolay V. Kukekov | director | 4524 WESTWAY AVE, DALLAS TX 75205 |
Mark Weinreb | director, 10 percent owner, officer: CEO and Chairman of the Board | STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458 |
Paul Jude Tonna | director | 69 CHICHESTER ROAD, HUNTINGTON NY 11743 |
A. Jeffrey Radov | director | 8 WALWORTH AVENUE, SCARSDALE NY 10583 |
Robert Paccasassi | officer: VP, Quality and Compliance | C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747 |
Robert B Catell | director | 62 OSBORNE ROAD, GARDEN CITY NY 11530 |
Adam D. Bergstein | officer: SVP, Planning and Business Dev | 167 HAZEL AVENUE, GLENCOE IL 60022 |
John M Desmarais | director | 230 PARK AVENUE, NEW YORK NY 10169 |
Westbury Trust | 10 percent owner | VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000 |
From GuruFocus
By Marketwired • 02-27-2025
By ACCESSWIRE • 05-15-2024
By Marketwired • 09-19-2024
By Marketwired • 05-14-2024
By Marketwired • 11-12-2024
By Marketwired • 10-31-2024
By Marketwired • 02-10-2025
By Marketwired • 06-13-2024
By Marketwired • 08-13-2024
By Marketwired • 11-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.